Upstate Active Clinical Trials
Study Title:A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
What is the purpose of the study?The purpose of this study is to evaluate how effective MEDI8897 is at preventing lung disease caused by RSV and to evaluate the safety and tolerability of MEDI8897 in healthy preterm infants compared with placebo (a saline solution that looks like the study drug but it does not contain active ingredient). The study will also measure drug levels of MEDI8897 in the blood, as well as looking at days missed from work and daycare.
Upstate Institutional Review Board (IRB) Number:935423
Study Phase:Phase II
Patient Age Group:Children
Principal Investigator:Joseph B Domachowske
Who can I contact for more information?
Name: Lori J Ferguson